FDA advances Sarepta Therapeutics’ ELEVIDYS for Duchenne muscular dystrophy treatment

In a promising development for the treatment of rare diseases, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a frontrunner in precision genetic medicine, announced that the U.S. Food ... Read More